PHAT
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc. (PHAT) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.
Quantitative Factor Evaluation • Updated
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Subscribe to unlock
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-14 | B (3.3) | B+ (3.8) | B+ (3.7) | D+ (1.6) | C+ (2.6) | B- (3.0) |
| 2026-11-07 | B (3.3) | A- (3.9) | B+ (3.7) | D (1.5) | C+ (2.7) | B- (3.0) |
| 2026-10-31 | B (3.4) | A- (3.9) | A- (3.9) | D (1.4) | C+ (2.7) | B- (3.1) |
| 2026-10-24 | B (3.3) | A- (4.0) | B+ (3.8) | D- (1.1) | C+ (2.6) | B- (3.0) |
Showing the last month only. Subscribe for the full factor score history.
For more — Subscribe